FibroGen (FGEN) Set to Announce Quarterly Earnings on Monday

FibroGen (NASDAQ:FGEN - Get Free Report) is scheduled to announce its earnings results after the market closes on Monday, May 6th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.

FibroGen (NASDAQ:FGEN - Get Free Report) last issued its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.15). The firm had revenue of $27.14 million for the quarter, compared to analyst estimates of $40.00 million. On average, analysts expect FibroGen to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

FibroGen Stock Performance

FGEN stock traded up $0.03 on Tuesday, reaching $1.12. The company had a trading volume of 1,122,648 shares, compared to its average volume of 2,399,251. The company's fifty day moving average is $1.78 and its 200 day moving average is $1.22. The company has a market cap of $111.41 million, a P/E ratio of -0.38 and a beta of 0.70. FibroGen has a 1 year low of $0.33 and a 1 year high of $19.47.

Wall Street Analysts Forecast Growth

Separately, William Blair reissued a "market perform" rating on shares of FibroGen in a research note on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $17.00.

Insider Transactions at FibroGen

In other news, CEO Thane Wettig acquired 50,000 shares of the company's stock in a transaction dated Thursday, March 7th. The stock was acquired at an average cost of $1.91 per share, for a total transaction of $95,500.00. Following the acquisition, the chief executive officer now directly owns 470,178 shares in the company, valued at approximately $898,039.98. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 2.39% of the company's stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.